| Aug 14 |
Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
| Jul 10 |
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML
|
| Jun 14 |
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial
|
| Jun 12 |
Moleculin to Present at the Virtual Investor Pitch Conference
|
| Jun 7 |
Moleculin Biotech files for $200M mixed securities shelf
|
| Jun 5 |
Moleculin to Participate in the Virtual Investor Lunch Break Series
|
| May 16 |
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress
|
| May 16 |
Moleculin begins NIH-funded Phase II glioblastoma treatment trial
|
| May 15 |
Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)
|
| May 9 |
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
|
